ARTICLE | Clinical News

Eslicarbazepine acetate: Additional Phase III data

December 14, 2009 8:00 AM UTC

A subgroup analysis of patients receiving eslicarbazepine plus any concomitant antiepileptic drug from 3 placebo-controlled Phase III trials in 1,049 patients showed that 400, 800 and 1,200 mg once-daily eslicarbazepine significantly improved responder rates vs. placebo (p<0.0001 for all doses). Responder rates were highest in the 800 and 1,200 mg eslicarbazepine arms compared with placebo (36.3% and 43.5%, respectively, vs. 21.5% for placebo). Data were presented at the American Epilepsy Society meeting in Boston. ...